Evaluating CCoat Injections for Knee Osteoarthritis

Effectiveness and Safety of CCoat Intra-Articular Injections in Mild to Moderate Knee Osteoarthritis: Prospective, Placebo Controlled, Randomized, Double-Blinded Study

This study is testing whether CCoat injections can help people with mild to moderate knee osteoarthritis feel less pain and move better compared to a placebo.

Quick facts

• Phase: Not applicable
• Study type: Interventional
• Enrollment: 92 (estimated)
• Ages: 30 Years to 85 Years
• Sex: All
• Sponsor: Lipo-Sphere (Industry-sponsored)
• Drugs / interventions: Chemotherapy, radiation
• Locations: 3 sites (Ashdod and 2 other locations)
• Trial ID: NCT05771948 on ClinicalTrials.gov

What this trial studies

This clinical trial aims to assess the effectiveness and safety of CCoat, an intra-articular injection, in patients with mild to moderate knee osteoarthritis. Participants will receive either CCoat or a placebo injection, with follow-up evaluations occurring over a period of up to 26 weeks. The study will compare the efficacy of two different concentrations of CCoat against placebo, focusing on pain relief and functional outcomes. Safety will also be monitored through the reporting of adverse events during the study.

Who should consider this trial

Good fit: Ideal candidates are adults aged 30 to 85 with mild to moderate knee osteoarthritis and a specific level of pain.

Not a fit: Patients with severe osteoarthritis or other significant knee conditions may not benefit from this treatment.

Why it matters

Potential benefit: If successful, this treatment could provide significant pain relief and improved function for patients suffering from knee osteoarthritis.

How similar studies have performed: While similar approaches have been explored, the specific use of CCoat in this context is novel and has not been extensively tested in prior studies.

Eligibility criteria

Inclusion Criteria:

1. Subject has signed and dated the informed consent form
2. Age ≥30 and ≤ 85 years old
3. Pain in the intended study knee with an average VAS score (active) of ≥3 over the last week before screening.
4. Degenerative changes in the intended study knee that can be categorized as grade I -III- Kellgren Lawrence based upon standing anterior- posterior and lateral radiographsof the knee
5. Body Mass Index (BMI) between 18.5 and 38
6. A negative urine pregnancy test female patient with childbearing potential at Visit 1 prior to intra-articular injection of AqueousJoint.
7. If female, the subject must be either postmenopausal, OR permanently surgically sterile OR for women of childbearing potential using at least 2 methods of birth control that are effective from at least 30 days before Visit 1 through visit 26w (26 weeks post injection).
8. Are willing or able to comply with procedures required in this protocol.

Exclusion Criteria:

1. Osteoarthritis of the index knee graded 4 according to the Kellgren-Lawrence Grading
2. History of significant knee trauma or previous surgery of the intended study knee within the last 3 months preceding the screening
3. Pain in both knees with a VAS score of ≥5
4. Intra-articular injection to the intended study knee within 3 months before Screening
5. Significant instability of the index knee
6. Malalignment more than 10 degrees varus OR 10 degrees valgus according to standing X-ray
7. Intake of chronic pain medications (especially opioid pain relievers) without an option to pause for the period of the study
8. History of Psoriatic Arthritis, Rheumatoid Arthritis, or any other inflammatory condition associated with arthritis
9. Wound in the area of the intended study knee
10. Any known tumor of the index knee
11. Any known history of intra-articular or osseous infection of the index knee
12. Any evidence of active infection anywhere in the body. Urinary Tract Infection (UTI) patients can be included following antibiotic treatment, provided that two consecutive cultures are negative (taken within at least 2 weeks of each other)
13. Any known history of inflammatory arthropathy or crystal-deposition arthropathy
14. Any known systemic cartilage and/or bone disorder, such as but not limited to, chondrodysplasia or osteogenesis imperfecta
15. Body Mass Index (BMI) \> 38
16. Active malignances, excluding BCC.
17. Chemotherapy and/or radiation in the past 12 months
18. Known history of a severe allergic reaction
19. Patient who is pregnant or intends to become pregnant during the study
20. History of any significant systemic disease, such as but not limited to: HIV, hepatitis, HTLV, syphilis, and coagulopathies
21. A Known substance or alcohol abuse
22. Participation in other clinical trials within 60 days to before the study or concurrent with the study
23. Known insulin dependent diabetes mellitus
24. Unable to undergo X-ray

Where this trial is running

Ashdod and 2 other locations

• Assuta — Ashdod, Israel (Recruiting)
• Sheba Medical Center — Ramat Gan, Israel (Recruiting)
• Kaplan Medical Center — Reẖovot, Israel (Recruiting)

Study contacts

• Principal investigator: Michael Drexler, Prof. — Orthopedic department
• Study coordinator: Alisa Yelisov, SC

Conditions Knee Osteoarthritis